Test Code #

060

CPT Code(s) #

86800, 86376

Test Name

Autoimmune Thyroid Panel (includes Thyroglobulin and Thyroid peroxidase)

If Profile, Includes Tests:

N/A

Disease Name:

Autoimmune Thyroid Diseases

Type of Study:

Serum Studies

Methodology:

Fluoroenzyme immunoassay (FEIA)

Substrate:

N/A

Reference Range:

Thyroglobulin (Tg) (IU/mL)
• Negative <40
• Equivocal 40-60
• Positive >60

Thyroid Peroxidase (TPO) (IU/mL)
• Negative <25
• Equivocal 25-35
• Positive >35

Units:

IU/mL (International Units/mL)

Schedule:

Assay performed once every week. Report availability is within one week from the time of specimen receipt

Specimen Requirements:

Collect 5-10 ml of blood in a red top or serum separator tube. If possible, separate serum from clot and place into red capped tube provided with Beutner Laboratories collection kits. If separation facilities are not available, the blood can be sent in the tube used for collection.

Sample Stability:

Sample is stable at ambient temperature during shipment. If sample is stored prior to shipment, it is stable refrigerated (2-8ºC) up to five days and frozen (-20ºC or lower) up to one year

Clinical Relevance:

Anti-TPO and Anti-TG antibodies are observed in autoimmune thyroid diseases (AITD) such as Grave’s disease (GD) and Hashimoto’s thyroiditis (HT). The prevalence of anti-TPO and anti-TG antibodies is high in patients with GD and HT. Besides these, anti-TSHR (anti-thyroid-stimulating hormone receptor) antibodies are also observed in 90% GD patients but only in approximately 0-20% patients with HT. Anti-TG antibody prevalence ranges from 60–80% in HT patients and 50–60% in GD patients. Circulating Anti-TG antibodies can be detected in about 10% of healthy young subjects, in 15% of people >60 years of age and in 10–15% of patients with non-thyroid immune disorders such as rheumatoid arthritis, type 1 diabetes and celiac disease. About 20 - 25% of differentiated thyroid cancer patients have detectable anti-TG antibodies at diagnosis or during treatment. Anti TPO antibodies are detected in 90–95% of AITD patients. Approximately, 90% of Hashimoto’s thyroiditis, 80% of Grave’s disease and two-thirds of patients with postpartum thyroiditis have detectable TPO antibodies. TPO antibodies can also be found in non-thyroid autoimmune diseases and some normal subjects.

Question about this test? Contact us:

Thanks for submitting!